Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix

• Status: Recruiting
• Trial end date: 2021-06-30
• Target enrollment: 0
• Participant gender: Female

Summary

A prospective study of three different doses of Degarelix in late luteal phase of women undergoing ovarian stimulation for IVF

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Assisting Nature

Criteria

Inclusion Criteria:

• primary infertility

• age 18-39 years; body mass index (BMI) 18-29kg/m2;

• regular menstrual cycle of 26-35days,

• presumed to be ovulatory;

• early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).

Exclusion Criteria:

• women with diabetes and other metabolic disease

• women with heart disease, QT prolongation,heart failure

• elevated liver enzymes, liver failure, hepatitis

• women with inflammatory or autoimmune disease

• abnormal karyotype;

• polycystic ovarian syndrome,

• endometriosis stage III/IV;

• history of being a 'poor responder',

• defined as >20 days of gonadotrophin in a previous stimulation cycle, or any previous cancellation of a stimulation cycle due to limited follicular response, or development of less than 4 follicles 15 mm in a previous stimulation cycle; history of recurrent miscarriage; severe OHSS in a previous stimula- tion cycle or any contraindication for the use of gonadotrophins.